Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting

Table 1 Baseline characteristics of enrolled patients

Characteristic	All (n = 54)	GT1b (n = 40)	GT2a (n = 14)	P(1bvs2a)
Age	55.4 ± 16.6	57.2 ± 15.9	50.1 ± 18.1	0.175
Male/Female	29/25	21/19	8/6	0.764
HCV RNA log10 (IU/mL)	6.48 ± 0.97	6.63 ± 0.89	6.06 ± 1.1	0.058
PR(experienced/naive)	21/33	17/23	4/10	0.358
Non-cirrhotic/cirrhotic	34/20	24/16	10/4	0.446
LSM (kPa)	15.9 ± 14.1	17.5 ± 15.1	11.4 ± 9.8	0.162
FIB-4 score	4.07 ± 4.35	4.14 ± 3.53	3.87 ± 6.29	0.847
ALT (IU/L)	54.6 ± 36.3	57.4 ± 38.7	46.5 ± 27.9	0.339
AST (IU/L)	50.8 ± 33.1	50.6 ± 26.8	46.3 ± 37.1	0.555
eGFR(mL/min per 1.73 m2)	87.1 ± 19.5	87.2 ± 20.9	86.5 ± 15.7	0.908
Scr (μmol/L)	83.6 ± 17.9	83.3 ± 19.5	84.4 ± 12.9	0.848
UA (μmol/L)	320.8 ± 76.3	315.2 ± 78.5	337.4 ± 72.9	0.349
BUN (mmol/L)	5.17 ± 1.50	5.21 ± 1.52	5.12 ± 1.55	0.881
WBC (109/L)	4.85 ± 1.67	4.67 ± 1.65	5.35 ± 1.70	0.192
RBC (1012/L)	4.42 ± 0.64	4.40 ± 0.67	4.49 ± 0.59	0.652
HGB (g/L)	140.8 ± 17.2	139.9 ± 17.9	143.6 ± 15.6	0.492
PLT (109/L)	147.1 ± 65.1	143.0 ± 68.4	158.8 ± 55.0	0.439

HCV: Hepatitis C virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine; UA: Uric acid; BUN: Blood urea nitrogen; LSM: Liver stiffness measurement; eGFR: Estimated glomerular filtration rate.

Table 2 Change of clinical indices before and after combined directly acting antivirals treatment

	T0	T1	T2	P01	P12	P02	P(DAAs*Time)
FIB-4 score	4.07 ± 4.35	2.94 ± 2.76	2.61 ± 2.21	0.001	0.003	< 0.001	0.399
ALT (IU/L)	54.6 ± 36.3	20.3 ± 13.3	17.1 ± 6.9	< 0.001	0.061	< 0.001	0.594
AST (IU/L)	50.8 ± 33.1	24.4 ± 10.4	22.4 ± 7.0	< 0.001	0.006	< 0.001	0.733
eGFR(mL/min/1.73 m2)	87.1 ± 19.5	81.2 ± 20.0	83.6 ± 21.2	0.001	0.174	0.097	0.646
Scr (μmol/L)	83.6 ± 17.9	88.8 ± 19.4	86.8 ± 19.1	< 0.001	0.137	0.039	0.481
UA (μmol/L)	320.8 ± 76.3	354.5 ± 87.6	345.9 ± 89.4	< 0.001	0.212	0.001	0.299
BUN (mmol/L)	5.17 ± 1.50	5.12 ± 1.40	5.65 ± 1.80	0.757	0.003	0.009	0.858
WBC (109/L)	4.85 ± 1.67	4.91 ± 1.54	5.00 ± 1.34	0.725	0.595	0.342	0.536
RBC (1012/L)	4.42 ± 0.64	4.43 ± 0.68	4.50 ± 0.68	0.822	0.345	0.223	0.023
HGB (g/L)	140.8 ± 17.2	139.4 ± 20.9	141.1 ± 21.1	0.467	0.443	0.860	0.026
PLT (109/L)	147.1 ± 65.1	153.6 ± 67.5	158.2 ± 65.9	0.053	0.117	0.008	0.540

T0: Baseline; T1: End of treatment; T2: 24 wk after the end of treatment. P01: Significance of difference between T0 and T1; P12: Significance of difference between T1 and T2; P02: Significance of difference between T0 and T2; P(DAAs*Time): Interactive effects of DAAs regimens and time points on the changes of renal function indices. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine; UA: Uric acid; BUN: Blood urea nitrogen; LSM: Liver stiffness measurement; eGFR: Estimated glomerular filtration rate; DAAs: Directly acting antivirals.

Table 3 Frequency of adverse events during combined directly acting antivirals treatment

Adverse event	n (%)
Fatigue	9 (16.7)
Headache	4 (7.4)
Anorexia	4 (7.4)
Insomnia	3 (5.6)
Anemia	2 (3.7)
Pruritus	1 (1.9)
Anxiety	1 (1.9)
Renal area pain	1 (1.9)
Treatment discontinuation	1 (1.9)
Total	18 (33.3)